Clinical Trial Update: Endoscopic Gastric Mucosal Ablation (GMA) of Class III Obesity [NA]

View source ↗

Summary

Clinical trial update for endoscopic gastric mucosal ablation (GMA) in class III obesity indicates the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Morbid Obesity
• Obesity

Drugs mentioned

• Endoscopic Gastric Mucosal Ablation (GMA)

Snippet

Sponsor: Erbe Elektromedizin GmbH | Conditions: Adiposity, Morbid | NA | Status: ACTIVE_NOT_RECRUITING